GARDP is a global not-for-profit developing and making available lifesaving and lifechanging treatments for drug-resistant infections. For everyone who needs them.

GARDP’S Work in North America and Globally

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing treatments for the drug-resistant bacterial infections posing the greatest threat to health. To do this we bring together governments, companies, research organizations, and civil society to develop treatments and ensure responsible and sustainable access in North America and globally.

 

This includes sponsoring trials, driving research of treatments for children and vulnerable populations, generating evidence to guide treatment use and inform policies, and advocating for change. We also foster antibiotic research and development by sharing knowledge, facilitating scientific exchange, and strengthening research capacity.

 

The Power of
Partnerships

Drug-resistant infections don’t know borders and neither can our responses. These bacteria can infect anyone, of any age, but it is the most vulnerable – children, the elderly, and people with weakened immune systems – who are hit first and hardest. We work hand in hand with partners in North America and around the world to power our progress in the development of five new treatments for the highest priority drug-resistant infections and to ensure we are meeting the needs of the most vulnerable.

HOW WE DO IT

Our work is focused on treatments for drug-resistant bacterial infections identified by the Centers for Disease Control and Prevention and the World Health Organization as being in most urgent need of new drugs. Our research and development efforts also prioritize people disproportionately affected by drug resistance, including babies, children, and hospitalized people.

 

To do this we’re working on research and development projects with more than 60 partners in 22 countries, including in North America. For example, we’re partnering with the U.S.-based biotech Entasis Therapeutics on the development of a new antibiotic active against resistant strains of gonorrhea, including sponsoring a phase 3 trial of this drug in the U.S., Netherlands, Thailand, and South Africa.

ANTIBIOTICS FOR ALL IN NEED

In many places around the world, people can’t access lifesaving and lifechanging antibiotics. We work to ensure antibiotics are affordable and responsibly available to the people who need them most.

OUR FUNDRAISING MODEL

Our work is made possible through the generous support of our donors, including governments, foundations, the private sector, and philanthropic and individual funders. Their donations allow us to research treatments for neglected diseases like neonatal sepsis, which globally is the leading cause of death in children under five. They allow us to sponsor clinical trials for a new drug for gonorrhea, which is on the rise in North America and around the world. We are also contributing to new treatments for hospital-acquired infections, which are responsible for 98,000 deaths every year in the U.S. alone.

OUR FUNDING
PARTNERSHIPS

Partnerships are at the heart of our success in developing new and improved treatments. GARDP is extremely grateful for the commitment of our funders in supporting our work to develop new treatments to address the silent pandemic of antibiotic resistance. Thank you.

GARDP North America Board Members

Karen M. Linehan

Board Member

Over 30 years of international experience in large pharmaceutical companies.

Paul Model

Board Member

Extensive experience in the fields of drug development, medical technology, and the formation and financing of companies in the fields of pharmaceuticals, biotechnology, and medical devices.

Jimmy Kolker

Board Member

Retired U.S. Ambassador & Former Assistant Secretary for Global Affairs of U.S. Department of Health and Human Services.

Dr. Prabhavathi Fernandes

Board Member and Chair of Scientific Advisory Committee

More than 35 years of experience in drug discovery and development in large pharmaceutical and biotechnology companies.

Dr. Sara Elizabeth Cosgrove

Board Chair

Associate Hospital Epidemiologist and Professor of Medicine at Johns Hopkins Hospital.

“An­timi­cro­bial resistance is now a leading cause of death worldwide. We must accelerate the development of new diagnostics, treatments, and vaccines as was done for COVID-19 and ensure they are accessible to all who need them. In partnership with GARDP, GARDP North America plays a vital role in developing new treatments for resistant infections and making them available to those who need them most, par­tic­u­larly newborns and children, the elderly, and hos­pi­tal­ized people.”

- Dr. Sara Cosgrove, Board Chair of GARDP North America

GARDP North America Team

Andrew Betts

Executive Director of GARDP North America

Andy joined GARDP NA in August 2022. He previously served as President and CEO of the Polycystic Kidney Disease Foundation based in Kansas City, Missouri, where he was instrumental in helping to secure the first US-approved treatment for a vastly unknown disease, and raised over $70M. Prior to this role, Andy served as the Executive Director for Development at The Salvation Army, Kansas & Missouri, overseeing the development and marketing teams across 28 cities and achieving annual revenues of $50M+.

Subasree Srinivasan

Medical Director

Suba is an experienced infectious disease physician with extensive industry and public health experience. Educated in India, Suba has lived in the U.S. for the last 30 years. She has worked in clinical and public health practice, and has had a number of senior medical and pharmacovigilance roles in drug development in companies such as Pfizer, BMS, and Alexion Pharmaceuticals.

Take action now. Fund our Work.